Assessment of D-Dimer and Ferritin as Predictive Biomarkers for Thromboembolic Events in Hospitalized COVID-19 Patients at Modares Hospital: A Retrospective Study
Abstract
Background: The COVID-19 pandemic has been associated with a significant prevalence of thromboembolism. This study aimed to identify the predictive effect of D-dimer and ferritin on thromboembolism occurrences in hospitalized COVID-19 patients.
Methods: This retrospective study examined 304 patients with COVID-19, with a mean age of 62.33 ± 17 years, hospitalized at Modares Hospital from March 2020 to March 2021. The case group (PTE) comprised patients who experienced thrombosis complications during hospitalization (152 patients), while the control group (Non-PTE) consisted of patients who did not encounter thrombosis complications during their hospital stay (152 patients). Demographic data, clinical information, and laboratory findings were gathered and documented from patient records. The study examined the impact of D-dimer and ferritin as predictors of thromboembolism in patients.
Results: In this study, 100 patients died, with 75 (75%) of these fatalities occurring in the PTE group. The results indicated that PTE patients exhibited higher BMI (28.36 ± 1.87 vs. 27.76 ± 1.31 kg/cm², P<0.001), longer hospital stays (11.2 vs. 8.5 days, P=0.0009), increased ICU admissions (61.8 vs. 26.3%, P<0.001), higher smoking rates (21.9 vs. 4.8%, P<0.001), and greater prevalence of chronic lung disease (13.2 vs. 2.6%, P=0.001) compared to non-PTE patients. Analysis of the laboratory findings indicated a significant increase in lymphocyte count (P=0.034) and C-reactive protein (CRP) 3+ levels (P=0.04) in the PTE group compared to the non-PTE group. The D-dimer concentration in the PTE group was 4178.80 ± 1148.78 ng/ml, while in the non-PTE group it was 606.04 ± 656.86 ng/ml (1.03 OR, 95% CI=1.04-1.02, P<0.001). The ferritin level in the PTE group was recorded at 1639.33 ± 514.38, while in the Non-PTE group, a measurement of 420.48 ± 322.65 ng/ml was recorded (OR: 1.06, CI95%=1.07-1.04, P<0.001).
Conclusion: Elevated serum levels of ferritin and D-dimer in COVID-19 patients correlate with an increased risk of thromboembolism. Consequently, elevated concentrations of these parameters in hospitalized patients should serve as a warning to clinicians, necessitating careful attention and prompt treatment interventions.
[2] Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618.
[3] Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al. Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med. 2020;1(8).
[4] Huyut MT, Huyut Z. Effect of ferritin, INR, and D-dimer immunological parameters levels as predictors of COVID-19 mortality: A strong prediction with the decision trees. Heliyon. 2023;9(3).
[5] Sadeghi S, Nasirian M, Keivany E, Nasri P, Mirenayat MS. The demographic, clinical, and medical manifestations of pulmonary thromboembolism development in COVID-19. Blood Res. 2021;56(4):293-300.
[6] Sakr Y, Giovini M, Leone M, Pizzilli G, Kortgen A, Bauer M, et al. The clinical spectrum of pulmonary thromboembolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A European case series. J Crit Care. 2021;61:39-44.
[7] Lin S-h, Zhao Y-s, Zhou D-x, Zhou F-c, Xu F. Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome. Genes Dis. 2020;7(4):520-7.
[8] Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, Shoenfeld Y. Ferritin–from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778.
[9] Cheng L, Li H, Li L, Liu C, Yan S, Chen H, Li Y. Ferritin in the coronavirus disease 2019 (COVID‐19): a systematic review and meta‐analysis. J Clin Lab Anal. 2020;34(10):e23618.
[10] Liu H, Guo N, Zheng Q, Zhang Q, Chen J, Cai Y, et al. Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2024;24(1):324.
[11] Jia J, Wang M, Meng J, Ma Y, Wang Y, Miao N, et al. Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still’s disease pathogenesis. Nat Commun. 2022;13(1):6804.
[12] Middleton EA, He X-Y, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136(10):1169-79.
[13] Ahmad F, Kannan M, Ansari AW. Role of SARS-CoV-2-induced cytokines and growth factors in coagulopathy and thromboembolism. Cytokine Growth Factor Rev. 2022; 63:58-68.
[14] Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020;13(11):1265-75.
[15] Ventura-Díaz S, Quintana-Pérez JV, Gil-Boronat A, Herrero-Huertas M, Gorospe-Sarasúa L, Montilla J, et al. A higher D-dimer threshold for predicting pulmonary embolism in patients with COVID-19: a retrospective study. Emerg Radiol. 2020;27:679-89.
[16] Ebrahimi M, Ahmadieh H, Rezaei Kanavi M, Safi S, Alipour-Parsa S, Advani S, et al. Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications. Front Med. 2025;11:1497750.
[17] Ebrahimi M, Fonarow GC. Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes. Am Heart J. 2025;. S0002-8703 (25) 00008-0.
[18] Omidi F, Sadeghi S, Kachoueian N, Ebrahimi M. A case report of diabetic ketoacidosis due to endocarditis of the mitral valve. Clin Case Rep. 2024;12(5):e8824.
[19] Reina-Reina A, Barrera JM, Maté A, Trujillo J, Valdivieso B, Gas M-E. Developing an interpretable machine learning model for predicting COVID-19 patients deteriorating prior to intensive care unit admission using laboratory markers. Heliyon. 2023;9(12).
[20] Mulder MM, Brandts L, Brüggemann RA, Koelmann M, Streng AS, Olie RH, et al. Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort. Thromb J. 2021;19(1):35.
| Files | ||
| Issue | Article in Press |
|
| Section | Research Article(s) | |
| Keywords | ||
| COVID-19 thromboembolism prognosis D-dimer ferritin | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
